CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), has announced the pricing of its follow-on public offering of 5 million common shares at a public offering price of US$90 per common share, for total gross proceeds of approximately US$450 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 750,000 common shares at the public offering price, less underwriting discounts and commissions. All of the common shares are being offered by CureVac. The offering is expected to close on February 1, 2021, subject to satisfaction of customary closing conditions.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with associates Adam Johnson, Patrick Maguire, and MacLane Taggart.